Geschäftsbericht der Lindenhofgruppe 2021

Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperationspartner / Sponsor A Phase III, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrol-izumab as an Induction and Maintenance Treatment for Patients with Moderately to Severely Active Crohn’s Disease (ETRO_144) Gastroenterologie Prof. Dr. med. Frank Seibold Hoffmann-La Roche/ Genentech An Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn’s Disease Previously Enrolled in the Etrolizumab Phase III (ETRO_145) Gastroenterologie Prof. Dr. med. Frank Seibold Hoffmann-La Roche/ Genentech An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies (ETRO_951) Gastroenterologie Prof. Dr. med. Frank Seibold Hoffmann-La Roche/ Genentech Real-world non-Interventional, prospective, observational Study to describe real-world treatment patterns in patients on vedolizumab treatment, for moderate to severe active Crohn or Ulcerative Colitis. Gastroenterologie Prof. Dr. med. Frank Seibold Takeda A multicenter, observational cohort study of women undergoing Immediate breast Reconstruction following Mastectomy (IRMA) Gynäkologie und Geburtshilfe Dr. med. Ives Brühlmann Spital Thurgau, Brustzentrum, Campus Stiftung Lindenhof Bern (SLB) SLC7-mediated amino acid transport across the materno-fetal barrier: association to human disease Gynäkologie und Geburtshilfe Dr. med. Ruedi Moser-Hässig Institut für Biochemie und Molekulare Medizin der Universität Bern Revisiting the steroidogenic pathways in human placenta and primary human trophoblast cells Gynäkologie und Geburtshilfe Dr. med. Ruedi Moser-Hässig Institut für Biochemie und Molekulare Medizin der Universität Bern Materno-fetal transport of iron: association with human gestational diseases Gynäkologie und Geburtshilfe Dr. med. Ruedi Moser-Hässig Institut für Biochemie und Molekulare Medizin der Universität Bern Pre- versus sub-pectoral implant-based breast reconstruction after skinsparing mastectomy or nip- ple-sparing mastectomy (OPBC-02/ PREPEC): A pragmatic, multicenter, randomized, superiority trial Gynäkologie und Geburtshilfe Dr. med. Thomas Fischer Universitätsspital Basel, Campus Stiftung Lindenhof Bern (SLB) Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized phase III trial. (OPBC-03/ SAKK 23/16 /IBCSG 57-18 / ABCSG-53 / GBG-101) Gynäkologie und Geburtshilfe PD Dr. med. Gilles Berclaz Universitätsspital Basel, Campus Stiftung Lindenhof Bern (SLB) Maintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) Gynäkologie und Geburtshilfe Prof. Dr. med. Ralf Rothmund Swiss Go Trial Group, Campus Stiftung Lindenhof Bern (SLB) An international randomised trial of additional treat- ments for COVID-19 in hospitalised patients who are all receiving the local standard of care. (SOLIDARITY) Intensivmedizin Dr. med. Jan Wiegand World Health Organization, Centre hospitalier universitaire vaudois, Campus Stiftung Lindenhof Bern (SLB) 82 Geschäftsbericht 2021 Lindenhofgruppe Lehre und Forschung